title: [Peroral ciprofloxacin in the therapy of infections in oncology patients].
abstract: The authors give an account of their initial experience with oral ciprofloxacin (Ciprinol) in the treatment of various infections in 28 immunosuppressed oncological patients. A favourable effect--cure and improvement--were recorded in 72% of all treated patients. Unfavourable side-effects were observed in 4 of 28 patients, in two they were the reason for discontinuation of treatment.
authors: Katedra klinickej onkológie ILF, Bratislava.
authors: V
authors: V
authors: Krcméry
authors: M
authors: M
authors: Horníková
authors: I
authors: I
authors: Koza
authors: P
authors: P
authors: Fuchsberger
authors: S
authors: S
authors: Spánik
authors: J
authors: J
authors: Sufliarsky
authors: J
authors: J
authors: Mardiak
authors: L
authors: L
authors: Sitáni
authors: P
authors: P
authors: Milosovic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*
chemical_list: D002939:Ciprofloxacin
vernacular_title: Perorálny ciprofloxacín v liecbe infekcií u onkologických pacientov.